Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
RMD · NYSE · Healthcare
Fundamental quality
87
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $3,197M | $475M | $634M | $348M |
| 2022 | $3,578M | $779M | $216M | $492M |
| 2023 | $4,223M | $898M | $574M | $1,203M |
| 2024 | $4,685M | $1,021M | $1,302M | $459M |
| 2025 | $5,146M | $1,401M | $1,662M | -$551M |
Between 2021 and 2025, revenue went from $3,197M to $5,146M (+61%) and net income went from $475M to $1,401M (+195%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is Resmed Inc a profitable company?
Yes. Resmed Inc shows a net margin of 27.4% and an ROE of 23.4%, a sign of a profitable business.
Does Resmed Inc have a lot of debt?
No. Resmed Inc has a net cash position: more cash than debt.
Is Resmed Inc growing?
Its revenue has grown 12.3% annualized in recent years and its earnings per share 19.6%.
Does Resmed Inc generate cash?
Yes. It converts about 31.7% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Resmed Inc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →